The FDA on July 20, 2012 granted accelerated approval to KYPROLIS® for the treatment of patients with multiple myeloma who have received at least two prior therapies, including VELCADE® (Bortezomib) and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of the completion of the last therapy. KYPROLIS® is a product of Onyx Pharmaceuticals.
Bottom Ad
Advertisement
Subscribe
